MHRA 2030 Strategy to modernise patient-centred regulation for the era of AI and personalised medicines

The Medicines and Healthcare products Regulatory Agency (MHRA) has set out ambitious plans to translate cutting-edge scientific and technological innovation into better health outcomes for patients across all four nations of the UK, in its 2030 Strategy published today. Commitments made in the strategy will enable the regulator to keep pace with rapid advances in science, technology and personalised healthcare, to benefit patients, and position the UK as a leading place to develop, launch and use new medicines and technologies safely and effectively. By 2030 , the MHRA aims to be even more patient-centred, support patients having faster access to safe, effective treatments, and have more data-connectivity and global influence.

The strategy defines the MHRA’s mission to contribute to ‘health and prosperity for all, through scientific excellence’ and reaffirms its central purpose to protect patients, improve public health and enable faster access to innovation. We want patients to benefit faster from the latest medicines and technologies, while maintaining the highest standards of safety.